drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Inhaled monobactam antibiotic used in cystic fibrosis to treat chronic Pseudomonas aeruginosa infection.
nci_thesaurus_concept_id
C28845
nci_thesaurus_preferred_term
Aztreonam
nci_thesaurus_definition
A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum with bactericidal activity. Aztreonam preferentially binds to and inactivates penicillin-binding protein-3 (PBP-3), which is involved in bacterial cell wall synthesis, thereby inhibiting bacterial cell wall integrity and leading to cell lysis and death. This agent differs from other beta-lactam antibiotics because it is resistant to beta-lactamase hydrolysis, and it is usually used to treat infections caused by gram-negative aerobic microorganisms.
drug_mesh_term
Aztreonam
drug_category
SMALL MOLECULE DRUG
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Monocyclic beta-lactam (monobactam) antibiotic that selectively binds and inhibits penicillin-binding protein 3 (PBP-3), blocking peptidoglycan cross-linking and bacterial cell wall synthesis, leading to cell lysis and death. Resistant to many beta-lactamases; active primarily against aerobic gram-negative bacteria, including Pseudomonas aeruginosa. Inhaled formulation is used in cystic fibrosis for chronic P. aeruginosa infection.
drug_name
Aztreonam
nct_id_drug_ref
NCT06159725